Stada’s Thornton & Ross Rivals Seretide In UK
Fixkoh Airmaster Launch Marks Subsidiary’s First Venture Into Respiratory Arena
Stada’s Thornton & Ross UK subsidiary has launched a generic version of Seretide, known as Advair in the US, marking its first push into the respiratory arena.
You may also be interested in...
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
Stada saw a small drop in both sales and profitability for its Generics division, but insisted the firm’s “strong position in generics,” alongside its leading position in consumer healthcare and growing specialty offering, “put the group on a sustainable growth course.”
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.